Company profile
Seres Therapeutics, Inc.
NASDAQ:MCRBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SER-287 | phase2 | — | 2 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04995653 | phase1 | completed | 2021-11-24 | 2024-07-23 | Seres Therapeutics, Inc. | A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT |
| NCT03759041 | phase2 | terminated | 2018-12-19 | 2021-05-28 | Seres Therapeutics, Inc. | A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis |
| NCT02618187 | phase1 | completed | 2016-01-13 | 2017-12-06 | Seres Therapeutics, Inc. | A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis |
| NCT03183128 | phase3 | completed | 2017-07-10 | 2020-07-03 | Seres Therapeutics, Inc. | ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection |
| NCT03183141 | phase3 | completed | 2017-10-23 | 2022-04-29 | Seres Therapeutics, Inc. | ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection |
FDA applications (0)
No records yet.